Managing Adverse Events Associated With Immunotherapy in Bladder Cancer
Joaquim Bellmunt, MD, PhD, shares his recommendation in how to manage the side effects of immunotherapy as a monotherapy, particularly PD-1/PD-L1, in patients with bladder cancer.
Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, shares his recommendation for how to manage the side effects of immunotherapy as a monotherapy, particularly PD-1/PD-L1 agents, in patients with bladder cancer.
Bellmunt emphasizes that the side effects do not always appear right away in this patient population. If a side effect is not recognized early enough, it can become life threatening for a patient.
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More
